nasopharyngeal-carcinoma

Documents about nasopharyngeal-carcinoma

• Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer#279520ClinicalTrials.gov
• Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer#876461ClinicalTrials.gov
• Nimotuzumab for Recurrent Nasopharyngeal Carcinoma#892156ClinicalTrials.gov
• Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer#28329ClinicalTrials.gov
• Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma#894715ClinicalTrials.gov
• Immune Score Based Radiomics in Nasopharyngeal Carcinoma#890605ClinicalTrials.gov
• Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure#1211265ClinicalTrials.gov
• Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer#1397815ClinicalTrials.gov
• Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma#916010ClinicalTrials.gov
• Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)#1396641ClinicalTrials.gov
• GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma#1295846ClinicalTrials.gov
• Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)#429752ClinicalTrials.gov
• Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma#1295269ClinicalTrials.gov
• Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma#245487ClinicalTrials.gov
• Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma#886438ClinicalTrials.gov
• Prognostic Value of TIL in Nasopharyngeal Carcinoma#1044258ClinicalTrials.gov
• Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening#1463951ClinicalTrials.gov
• A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma#1171689ClinicalTrials.gov
• Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma#373615ClinicalTrials.gov
• A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma#478239ClinicalTrials.gov
• Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma#902841ClinicalTrials.gov
• Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma#1095156ClinicalTrials.gov
• MK-2206 in Recurrent Nasopharyngeal Carcinoma#1124889ClinicalTrials.gov
• SOX as Salvage Treatment in Nasopharyngeal Carcinoma#1246495ClinicalTrials.gov
• Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma#1294082ClinicalTrials.gov
• Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy#885897ClinicalTrials.gov
• Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone#902067ClinicalTrials.gov
• Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma#1485962ClinicalTrials.gov
• Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma#1228492ClinicalTrials.gov
• Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma#160338ClinicalTrials.gov
• Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma#807751ClinicalTrials.gov
• Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma#905742ClinicalTrials.gov
• Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma#1072791ClinicalTrials.gov
• Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma#1308851ClinicalTrials.gov
• Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma#1337513ClinicalTrials.gov
• Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma#1477750ClinicalTrials.gov
• Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)#674906ClinicalTrials.gov
• Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma#1102430ClinicalTrials.gov
• Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer#1261240ClinicalTrials.gov
• Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma#184862ClinicalTrials.gov
• Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma#414500ClinicalTrials.gov
• Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma#899602ClinicalTrials.gov
• Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy#1104214ClinicalTrials.gov
• Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma#1432200ClinicalTrials.gov
• Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial#279488ClinicalTrials.gov
• Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy#805754ClinicalTrials.gov
• Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma#1212039ClinicalTrials.gov
• Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma#1246790ClinicalTrials.gov
• Adaptive Immunotherapy for Nasopharyngeal Carcinoma#143543ClinicalTrials.gov
• SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.#852393ClinicalTrials.gov